We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Promising drug discovery for the effects of Alzheimer’s disease

Promising drug discovery for the effects of Alzheimer’s disease content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Scientists from the University of South Australia, along with colleagues from Third Military Medical University in Chongqing, China, have discovered the drug Edaravone can alleviate the progressive cognitive deficits of Alzheimer's disease, a major social and economic burden worldwide.

The discovery has been published in the journal Proceedings of the National Academy of Sciences.

Edaravone is currently available only in some Asian countries for the treatment of ischemic stroke -- the most common type of stroke which is caused by blood clots.

Lead researcher Professor Xin-Fu Zhou, who is UniSA's Research Chair in Neurosciences, says Edaravone can alleviate Alzheimer's disease pathologies and improve functions of learning and memory -- in a mouse model of the disease -- by multiple mechanisms.

"Edaravone can bind the toxic amyloid peptide which is a major factor leading to degeneration of nerve cells," Prof Zhou says.

Prof Zhou says lessons from failures of current clinical trials suggest that targeting multiple key pathways of the Alzheimer's disease pathogenesis is necessary to halt the disease progression.

"Edaravone can suppress the toxic functions of amyloid beta to nerve cells -- it is a free radical scavenger which suppresses oxidative stress that is a main cause of brain degeneration," he says.

"The drug can suppress the production of amyloid beta by inhibiting the amyloid beta production enzyme. It also inhibits the Tau hyperphosphorylation which can generate tangles accumulated in the brain cells and disrupt brain functions."

The research is a collaboration between Prof Zhou's lab within UniSA's Sansom Institute for Health Research and School of Pharmacy and Medical Sciences, and labs led by Prof Yanjiang Wang in Chongqing, China.

The researchers stress Edaravone should not be used for Alzheimer's patients before appropriate clinical trials are undertaken. Prof Zhou is seeking investment and partnership opportunities to further the research.

Note: Material may have been edited for length and content. For further information, please contact the cited source.

University of South Australia   press release


Shu-Sheng Jiao, Xiu-Qing Yao, Yu-Hui Liu, Qing-Hua Wang, Fan Zeng, Jian-Jun Lu, Jia Liu, Chi Zhu, Lin-Lin Shen, Cheng-Hui Liu, Ye-Ran Wang, Gui-Hua Zeng, Ankit Parikh, Jia Chen, Chun-Rong Liang, Yang Xiang, Xian-Le Bu, Juan Deng, Jing Li, Juan Xu, Yue-Qin Zeng, Xiang Xu, Hai-Wei Xu, Jin-Hua Zhong, Hua-Dong Zhou, Xin-Fu Zhou, Yan-Jiang Wang. Edaravone alleviates Alzheimer’s disease-type pathologies and cognitive deficits.   Proceedings of the National Academy of Sciences, Published Online April 6 2015. doi: 10.1073/pnas.1422998112